Literature DB >> 1322314

A long synthetic peptide containing a nuclear localization signal and its flanking sequences of SV40 T-antigen directs the transport of IgM into the nucleus efficiently.

Y Yoneda1, T Semba, Y Kaneda, R L Noble, Y Matsuoka, T Kurihara, Y Okada, N Imamoto.   

Abstract

Synthetic short peptides containing only the nuclear localization signal (NLS) direct the transport of nonnuclear proteins into the nucleus. As a conjugate of the synthetic peptide with immunoglobulin M (IgM) did not enter the nucleus, there was believed to be a size limit for nuclear transport of NLS-conjugated proteins. However, we found that IgM conjugated with purified nucleoplasmin, a nuclear protein of Xenopus oocytes, rapidly accumulated in the nucleus. For direct comparison with the short peptide, we prepared a long peptide containing the NLS and its flanking sequences of SV40 large T-antigen and its mutated long peptide, in which possible phosphorylation sites located at the amino terminal of the NLS were changed to alanine. Kinetic experiments showed that wild-type long peptide-IgM conjugates were almost entirely taken up into the nucleus within 30 min after their injection, whereas almost 60 min was required for the mutated long peptide-IgM conjugates to enter the nucleus of all the cells examined, and there was no apparent accumulation of short peptide-IgM conjugates in the nucleus within 60 min. These results indicate that even when the kinetics of transport are affected by amino acid substitutions, the long peptide directs the transport of large molecules such as IgM into the nucleus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322314     DOI: 10.1016/0014-4827(92)90279-h

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

Review 1.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

2.  Development of a novel DsRed-NLS vector with a monopartite classical nuclear localization signal.

Authors:  Hee Sang You; Yeon Jeong Ok; Eun Jeong Lee; Sang Sun Kang; Sung Hee Hyun
Journal:  3 Biotech       Date:  2019-05-24       Impact factor: 2.406

Review 3.  The regulation of protein transport to the nucleus by phosphorylation.

Authors:  D A Jans
Journal:  Biochem J       Date:  1995-11-01       Impact factor: 3.857

4.  Molecular and structural analysis of nuclear localizing anti-DNA lupus antibodies.

Authors:  M H Foster; T Kieber-Emmons; M Ohliger; M P Madaio
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

5.  Restoration of CAPAN-1 cells with functional BRCA2 provides insight into the DNA repair activity of individuals who are heterozygous for BRCA2 mutations.

Authors:  Jeffrey T Holt; William P Toole; Vedang R Patel; HeeYoung Hwang; Erika T Brown
Journal:  Cancer Genet Cytogenet       Date:  2008-10-15

6.  Deoxyribonuclease I (DNAse I). A novel approach for targeted cancer therapy.

Authors:  H Linardou; M P Deonarain; R A Spooner; A A Epenetos
Journal:  Cell Biophys       Date:  1994

7.  Targeted disruption of transcriptional regulatory function of p53 by a novel efficient method for introducing a decoy oligonucleotide into nuclei.

Authors:  Masakiyo Sakaguchi; Takamasa Nukui; Hiroyuki Sonegawa; Hitoshi Murata; Junichiro Futami; Hidenori Yamada; Nam-ho Huh
Journal:  Nucleic Acids Res       Date:  2005-05-26       Impact factor: 16.971

8.  Antibodies against 70-kD heat shock cognate protein inhibit mediated nuclear import of karyophilic proteins.

Authors:  N Imamoto; Y Matsuoka; T Kurihara; K Kohno; M Miyagi; F Sakiyama; Y Okada; S Tsunasawa; Y Yoneda
Journal:  J Cell Biol       Date:  1992-12       Impact factor: 10.539

9.  Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies.

Authors:  A M Mhashilkar; J Bagley; S Y Chen; A M Szilvay; D G Helland; W A Marasco
Journal:  EMBO J       Date:  1995-04-03       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.